Derivative weighted active insulin control algorithms and intensive care unit trials

Carmen V. Doran\textsuperscript{a}, J. Geoffrey Chase\textsuperscript{a,}\textsuperscript{*}, Geoffrey M. Shaw\textsuperscript{b}, Katherine T. Moorhead\textsuperscript{a}, Nicolas H. Hudson\textsuperscript{a}

\textsuperscript{a}Department of Mechanical Engineering, University of Canterbury, Private Bag 4800, Christchurch, New Zealand
\textsuperscript{b}Department of Intensive Care Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch Hospital, P.O. Box 4710, Christchurch, New Zealand

Received 16 March 2004; accepted 5 October 2004

Abstract

Critically ill-patients often experience stress-induced hyperglycaemia. This research demonstrates the effectiveness of a simple automated insulin infusion for controlling the rise and duration of blood glucose excursion in critically ill-patients. Heavy derivative controllers derived from a simple, two-compartment model reduced blood glucose excursion 79–89\% after a glucose input in proof-of-concept clinical trials. Modelled performance is very similar to clinical results, including a strong correlation between modelled and actual insulin consumed, validating the fundamental models and methods. However, the need for additional dynamics in the model employed is clearly illustrated despite capturing the essential dynamics for this problem.

Keywords: Biomedical control; Physiological models; PD controllers; Non-linear models

1. Introduction

Diabetes is a disorder of the metabolism whereby insufficient insulin is produced by the beta cells, and as such, blood glucose cannot be transported out of the blood. Lack of insulin results in blood glucose levels remaining dangerously high, which untreated over time leads to costly complications, including kidney failure, blindness, nerve damage, heart attack and stroke. Over 120 million people are affected by diabetes worldwide, and this number is expected to rise to 300 million by the year 2025 (Thomson et al., 2001).

Critically ill-patients often experience stress-induced hyperglycaemia and high levels of insulin resistance, even if they have no history of diabetes (Capes, Hunt, Malmberg, & Gerstein, 2000; Christensen, 2001; Ousman, 2002; Umpierrez et al., 2002; Bloomgarden, 2003; Finney, Zekveld, Elia, & Evans, 2003; Van den Berghe et al., 2001, 2003). Hyperglycaemia can lead to an increased risk of further complications such as severe infections, myocardial infarctions (Capes et al., 2000), polyneuropathy, and multiple-organ failure (Van den Berghe et al., 2001). Tight glucose control has been shown to reduce intensive care unit (ICU) patient mortality by as much as 45\% (Van den Berghe et al., 2001). Current protocols lack the consistency to ensure tight control of blood glucose levels, while automated algorithms are still in their infancy.

While ICU patients are often sedated and in a highly monitored state, they are extremely diverse in the causes and dynamics of their hyperglycaemia. As a result, their response to a glucose input can vary significantly due to
equally extreme variations in insulin levels, effective insulin utilization, glucose absorption and a variety of other factors. Hence, these trials represent a fairly extreme test of the ability of the models and control systems developed, and highlight the need for simplicity in a clinical environment.

Automated treatment promises better control of blood glucose with higher consistency and an associated reduction in diabetes related complications. Existing insulin pumps and emerging non-invasive and semi-invasive glucose monitoring systems may be easily interconnected to realise a closed loop system. Ultimately, the control unit should be able to automate 90–95% of the day-to-day insulin care. Therefore, the goal is to control the essential dynamics rather than all of the dynamics and exceptional behaviours.

Years of research on modelling and managing diabetes have led to no shortage of theoretical automated solutions (e.g. Ollerton, 1989; Kienitz, & Yokoyama, 1993; Fisher, 1991; Furler, Kraegen, Smallwood, & Chisholm, 1985). However, due to either the complexity of the proposed implementation, models that are not physiologically verified, or lack of required data these solutions have not been trialled. Several researchers have examined the analysis and automation of insulin administration as reviewed by Lehman and Deutsch (1996). In each case, the focus has been on controlling absolute blood glucose excursion rather than the shape of the glucose curve, as is done in heavy derivative control (Chase, Lam, Lee, & Hwang, 2002).

Practical solutions that have reached implementation have been applied primarily to ambulatory diabetic individuals and less often to the more difficult, hyperglycaemic critically ill patient who may not be insulin resistant when healthy. Those implemented in the critical care environment have been based on a sliding scale format to determine the insulin input as a function of blood glucose level alone (e.g. Chee, Fernando, & van Heerden, 2002; Van den Berghe et al., 2001, 2003). These approaches merely add consistency to a semi-automated fashion to the selection of insulin infusion level by medical staff. Since glucose level alone is the determining factor the control implemented is essentially pure proportional. To the best of the author’s knowledge, no model based automatic control methods have been clinically trialled for critical care.

Prior work in tightly controlling elevated blood glucose levels using heavy derivative control employed a physiologically verified three compartment model based on the work of Bergman, Finegood, and Ader (1985). Performance was shown to improve with decreased sensor lag and sampling period and the controlled solution outperformed the simulated normal human response at a sample period of 1 min (Lam, Lee, Hwang, Chase, & Wake, 2002). The primary feature of derivative weighted control is the focus on controlling the shape of the blood glucose curve rather than the absolute magnitude of blood glucose. This approach adds robustness because it can more readily account for varying rates of glucose absorption and other patient specific behaviours. The research presented here develops this heavy derivative control approach to a proof-of-concept clinical trial with ICU patients. Results are compared to predicted values to verify the modelling methods and overall approach to controlling blood glucose.

2. Clinical trial method

The proof-of-concept clinical trials conducted effectively simulate a true feedback control system with a 15-min sampling period, which works well and represents a realistic level of system performance (Chase et al., 2002; Chase, Shaw, Doran, Hudson, & Moorhead, 2003; Lam et al., 2002). They are designed specifically to test the effectiveness of the heavy derivative control methods under variable glucose inputs and to verify the simulations of the essential dynamics and design that led to them.

Qualifying patients had to be stable, have elevated blood glucose levels over 8 mmol/L (average blood glucose in a healthy individual is 4.5–5 mmol/L), have an arterial line and a nasogastric feed, and be expected to remain in the ICU for at least 3 days. In addition, patients with morbid obesity (BMI > 35 kg/m²) or neuromuscular blockade were not considered. The clinical trials are a 2-day procedure for each participant. The first day of the trial measures the uncontrolled glucose regulatory system response and the second day implements active insulin control. The Canterbury Ethics Committee granted ethics approval for these trials.

2.1. Clinical trial day one

The trial begins at 0700 h at which time the patient is fasted for 4 h. Blood glucose readings are taken every hour to determine a basal blood glucose level. At 1100 h, blood is taken for C-peptide and blood insulin tests to screen for insulin contamination and determine the basal insulin level, respectively. The patient is then given a 75 g oral glucose tolerance test (OGTT) glucose dose over 1 min via the nasogastric tube. Plasma glucose is measured at 15-min intervals until 1500 h. Paired samples are taken, with one analysed using a bedside Glucocard™ Test Strip 2 glucose testing kit and the other sent to the laboratory for comparison. The error in the absolute readings are approximately 7% for the Glucocard™ Test Strip 2 tests, and 3% for the laboratory tests at typical elevated blood glucose levels
2.2. Clinical trial day two

The procedure is repeated as per day one, however short acting soluble insulin with 0.2 U/ml in 0.9% saline is infused via an intravenous cannula using a Graseby 3500 syringe pump. Plasma glucose is measured at 15-min intervals as previously and the insulin infusion rate is manually adjusted every 15 min according to the heavy derivative control algorithm. This approach is designed to specifically test the algorithm. Hence, only glucose measurements were made to simulate a practical implementation and eliminate the impact of any specific equipment.

3. Mathematical modelling

Implementing tight glucose control in critically ill-patients via a fully automated insulin infusion system requires a simple model of the glucose regulatory system that accounts for the relationship between intravenous infusion of exogenous insulin and the measured blood glucose level. The initial physiologically verified model employed originated from the work of Bergman et al. (1985), utilising the concept of a remote compartment for the transport of insulin between the subcutaneous infusion site and its utilisation to reduce blood glucose levels.

ICU patients have direct arterial/venous lines that bypass the subcutaneous compartment in the three-compartment model, and require only two compartments. The first compartment models insulin uptake into the blood, and the second models blood glucose level and insulin mediated transport of glucose from the blood. The model is shown schematically in Fig. 1 and defined:

\[
\dot{G} = -p_G G - S_I (G + G_B) + P(t),
\]

\[
\dot{I} = -n(I + I_B) + \frac{u(t)}{V_I},
\]

where \( G \) (mmol/L) is the concentration of the plasma glucose above basal level, \( G_B \) (mmol/L), \( I \) (mU/L) is the concentration of the plasma insulin above basal level, \( I_B \) (mU/L), \( u(t) \) (mU/min) is the exogenous insulin infusion rate, \( P(t) \) (mmol/L/min) is the exogenous glucose input, \( V_I \) (L) is the volume of distribution, and \( n \) (min\(^{-1}\)) is the rate constant associated with the interstitial transfer of insulin to be utilised. \( p_G \) (min\(^{-1}\)) and \( S_I \) (L/mU/min) are patient specific parameters, where \( p_G \) is the fractional clearance of plasma glucose at basal insulin, and \( S_I \) is insulin sensitivity as described by Bergman et al. (1985). The model is therefore patient specific and is adapted to each person before a controller is developed.

Fig. 1 shows the fundamental physiological inputs to Eq. (1), specifically insulin and glucose. The insulin inputs on the left side are broken into endogenous, or basal, insulin production, \( I_B \), and exogenous insulin input, \( u(t) \), with their compartment dynamics defined by Eq. (2) resulting in the insulin input, \( I(t) \). The glucose inputs in the bottom of the figure are similarly categorised as endogenous, basal production from the liver, \( G_B \), and exogenous input, \( P(t) \), with no additional compartment dynamics. Eq. (1) is the pharmacodynamic equation for the utilisation of insulin and removal of glucose in the blood plasma and at interstitial sites in this simplified model, and its output is the net change of blood glucose from basal levels, \( G(t) \).

Additional model dynamics linking the two compartments in Eqs. (1) and (2) may be needed, however any missing dynamics would influence \( S_I \) and the insulin utilisation term with little effect on the ability to derive an appropriate controller that acts on blood glucose levels.
rise. More specifically, the upward rise of glucose concentration over the first 45–60 min does not depend heavily on this term, and it is this rise that the heavy derivative control focuses on limiting.

Hence, a second aspect of this research is to determine from the clinical results whether this simple control model lacks the complexity to sufficiently capture the essential dynamics required for model-based blood glucose control. Given the difficulty of modelling the dynamics of hyperglycaemic critical care patients due to their lack of diabetes history, high glucose intolerance and hyper-insulinemia, the simplest realistic model was used with the goal of adding critical dynamics as they became apparent from clinical results.

Controller parameter determination is therefore accomplished in three steps. First, data is gathered from an uncontrolled OGTT. Second, the patient specific parameters, $p_G$ and $S_I$, are obtained using unconstrained optimisation designed to minimise the difference between modelled and test behaviour. Finally, given a model that fits the error bounds of the uncontrolled patient data, particularly the initial rise, proportional-derivative (PD) control gains, $K_p$ and $K_d$, are developed using a second unconstrained optimisation to find derivative weighted gains that minimise the magnitude and duration of blood glucose excursion from the patient’s basal level for the same OGTT input.

### 3.1. Parameter determination

The total amount of glucose infused simulating an OGTT is 412 mmol, a value obtained by converting 75 g of glucose and assuming the patient has the glucose evenly distributed in a $V_f = 12$ L fluid volume with rate constant $n = 0.16$ (Furler et al., 1985; Bergman et al., 1985). To account for the different rates of uptake, the peak of the simulated exogenous glucose infusion profile, $P(t)$, is set at approximately 80% of the time required for the patient’s uncontrolled OGTT peak glucose reading, and modelled as a continuous log-normal function. Hence, the simulated and actual uptake rates for uncontrolled OGTT will be similar and the total glucose input will be identical.

A continuous function is fitted to the patient’s uncontrolled, day one, OGTT data using a log-normal function, which captures the fundamental dynamics of such data well (Lam et al., 2002). This function is used to derive a function, $G_{\text{patient}}$, which can be discretised for optimisation into a series of time points, $\bar{G}_m$, to enhance the number of points available for data fitting, where $\bar{G}_m$ includes the actual data points taken at the proper times. This approach effectively augments the data taken and smoothes out some of the noise. Similarly, the same data points can be obtained from a simulation of Eqs. (1) and (2), a set labelled $\bar{G}_m$, to enable a comparison between model and data in the optimisation routine. Unconstrained optimisation using Matlab is then used to determine $S_I$ and $p_G$, so that the square error defined below is minimised:

$$R = (\bar{G}_{\text{patient}} - \bar{G}_m)^T(\bar{G}_{\text{patient}} - \bar{G}_m) + e^{-p_G C} + e^{-S_I C},$$

where $C$ is a large positive constant (e.g. 1000 for this model), defined to ensure that $p_G$ and $S_I$ remain positive. These exponential terms add the constraints $p_G > 0$ and $S_I > 0$, creating an unconstrained optimisation problem, since meeting these terms are zero when the constraints are satisfied, and lead to a very large penalty otherwise.

By changing the discretisation of $G_{\text{patient}}$, certain points in the model solution and the continuous function $G_{\text{patient}}$ can be constrained to match more accurately. Typically, several extra time points around the peak of the glucose response curve are added to ensure the rise and inflection of the glucose curve are adequately captured. It is this rise and inflection that are critical for effective control of the blood glucose rise, as it is this portion of the curve that instigates the vast majority of the controlled insulin infusion input.

### 3.2. Control design

The controller determines the amount of exogenous insulin, $u(t)$, infused. The model is set to run with a 15 min sampling interval to match the clinical trial program. A heavy derivative PD controller is employed:

$$u(t) = \max[0, U_0(1 + K_p(G + G_{\text{prime}}) + K_d \dot{G})],$$

where $U_0$ (mU/min) is the basal insulin infusion rate typically equivalent to approximately 1 U/h. $K_p$ is the proportional gain and $K_d$ the much larger derivative gain (Lam et al., 2002). More specifically, the proportional gain is typically 20–50x smaller than the derivative gain so it dominates the control input during the rise and fall of blood glucose. Finally, $G_{\text{prime}}$ (mmol/L) is an offset term to the proportional control input, so a high basal glucose level, $G_B$, can be controlled to a lower target blood glucose level, $G_I$, by increasing $G_{\text{prime}}$, the difference between the target blood glucose level ($G_I$) and the actual, elevated basal blood glucose level ($G_B$):

$$G_{\text{prime}} = G_B - G_I.$$  

When $G_{\text{prime}}$ is more positive, the proportional feedback term is greater. The ‘max’ function, with argument ‘0’, in Eq. (4) ensures that negative insulin demands, encountered as blood glucose falls, are treated as a zero input.

It is important to note that the PD controller defined in Eqs. (4) and (5) is non-linear. More specifically, it only provides insulin for positive control inputs and does nothing when “negative insulin” is commanded. Per the work in Lam et al. (2002), the use of derivative focused PD control in this way helps predict glucose
surges, such as after a meal or OGTT input, and therefore provide the proper insulin, which in this case is much like a bolus injection. Similarly, when the glucose is falling the derivative is negative and no insulin is therefore commanded, which would destabilise this system by adding insulin to already falling blood glucose levels and resulting in hypoglycaemia. Therefore, this non-linear PD controller effectively avoids destabilising inputs with a derivative focused PD controller for this process, even though a small lag may occur between intravenous insulin infusion and its utilisation to reduce blood glucose.

The control gains are determined by minimising the objective function (R) defined:

\[
R = C_1 \left[ G(\tilde{t}) - G_i \right]^T \left[ G(\tilde{t}) - G_i \right] + C_2 \dot{G}(\tilde{t})^T \dot{G}(\tilde{t}) + e^{-K_d C_1} + e^{-K_p C_2},
\]

where \( C_1, C_2 \) and \( C \) are positive constants that weight each of their respective terms. The \( G(\tilde{t}) \) terms are the measured glucose data and in Eq. (6) are used to minimise the area between the blood glucose levels from the measured data and the target blood glucose levels, \( G_i \). Similarly, the \( \dot{G}(\tilde{t}) \) terms in the objective function minimise the slope of the output glucose levels, reducing oscillation in the blood glucose response curve, a problem that can occur if the gains are too large. The exponential terms in the objective function ensure that \( K_d \) and \( K_p \) remain positive, using the same approach as in Eq. (3). The control gains are patient specific, however typical ranges for \( K_d \) and \( K_p \) found in this study are (0.1–3) and (10–40), respectively, with a typical ratio of approximately 25 of \( K_d \) to \( K_p \). Overall, optimisation is employed not to find a best solution but to efficiently search a large domain of possible control gains.

Where a proportional controller only infuses significant insulin at elevated blood glucose levels, heavy derivative control predicts the approaching high blood glucose level from the steep gradient and infuses insulin pre-emptively, thus enabling a faster response to increasing blood glucose levels. This approach is similar to a healthy response to increasing blood glucose levels, where gastrointestinal hormones stimulate an anticipatory increase in insulin concentration in preparation for glucose and amino acids to be absorbed from a meal creating an initial insulin spike (Guyton and Hall, 1996).

Simulation by Lam et al. (2002) have shown that the heavy-derivative control method results in an infusion profile similar to a bolus with a background infusion as commonly done by diabetics. This bolus with a background infusion also mimics the post-prandial first and second phase insulin release exhibited by healthy individuals (Del Prato, Marchetti, & Bonadonna, 2002). An infusion that is proportional to blood glucose level alone will infuse insulin when blood glucose is still above the desired level but dropping rapidly, leading to an increased risk of hypoglycaemia (Lam et al., 2002). Pure proportional control will also not mimic the initial sharp, bolus-like, first-phase insulin release that occurs in normal individuals following a glucose input or challenge, as proportional control is strictly a function of the slower rising glucose level that initially starts at the basal level.

4. Clinical results and discussion

Table 1 gives the patient age, condition, insulin levels, \( G_B \), peak glucose levels, and patient specific parameters, \( p_G \) and \( S_I \), from day one of the trial. The four patients display a diverse range of glucose responses to the OGTT from relatively flat to extremely volatile. The insulin sensitivity values, \( S_I \), are of the same order or higher than existing data for sub-cutaneous delivery (Bergman, Phillips, & Cobelli, 1981; Avogaro, Bristow, Bier, Cobelli, & Toffolo, 1989). However, sub-cutaneous infusions can be subject to up to 20% losses in transportation (Kraegen and Chisholm, 1984). These losses are typically accounted for by a reduced value for \( S_I \), and for intra-venous infusion, the higher values might be expected.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Condition</th>
<th>Basal glucose, ( G_B ) (mmol/L)</th>
<th>Peak glucose (mmol/L)</th>
<th>Insulin level (pmol/L)</th>
<th>Patient specific parameters</th>
<th>Diabetic type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67</td>
<td>Kidney failure</td>
<td>9.5</td>
<td>11.5</td>
<td>70</td>
<td>0.1549</td>
<td>0.0317</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>ARDS, Tetraplegic</td>
<td>12.5</td>
<td>24.5</td>
<td>59</td>
<td>0.0187</td>
<td>1.1 \times 10^{-4}</td>
</tr>
<tr>
<td>3</td>
<td>75</td>
<td>Head injury</td>
<td>13.8</td>
<td>22.1</td>
<td>3</td>
<td>0.0074</td>
<td>0.0036</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>Sepsis</td>
<td>10.8</td>
<td>11.8</td>
<td>295 (infected sample)</td>
<td>0.1</td>
<td>0.0025</td>
</tr>
</tbody>
</table>
Patient 1 was a 67 year old female subject in the ICU for 3 days suffering from kidney failure. The kidneys can remove up to 30% of effective insulin, so kidney failure is an “insulin sparing” condition that can lead to a flatter glucose response (Charpentier, Riveline, & Varroud-Vial, 2000). The patient was both hyperglycaemic and somewhat hyper-insulinemic as well as indicated by a basal insulin level of 70 pmol/L.

Fig. 2 shows the measured and model predicted glucose response for day one (uncontrolled) and day two (controlled). The measured data is presented with the 7% error associated with GlucoCard\textsuperscript{TM} 2 (Arkray Inc, 2001) measurements. The magnitude and duration of blood glucose excursion from the basal level are reduced over 50%. The target sub-basal glucose level of 5.5 mmol/L was not fully reached, as the relatively low proportional control is not effective as the tail of the glucose response curve flattens off. This result is an example of the need for gain scheduling or a modified control approach in this flatter response regime. Also note that the uncontrolled response is relatively flat for an OGTT, which is a result of the patient’s relative hyper-insulinemia.

Overall, the automated algorithm provided rapid, effective control of the OGTT input and the simulated controlled response was an extremely good match for the measured data, as seen in Fig. 2. The difference in day one and day two basal levels is due to changes in feeding and insulin administration over the night between the OGTTs. Finally, the patient’s blood glucose concentration began to increase steadily back to 10 mmol/L after the controlled day two test when hospital staff returned to their sliding scale protocol, showing the need for, and effectiveness of, automated methods for tight glucose regulation.

Patient 2 was a 48 year old male tetraplegic with Acute Respiratory Distress Syndrome (ARDS). This patient’s history exhibited an extremely variable response to most medications and this experience was reiterated during the trial. As shown in Fig. 3, the patient’s glucose absorption was much faster on day two, due to delayed gastric emptying on day one. The response on day two also shows the possible effect of unmodelled insulin accumulation dynamic at 200 min. The faster day two gastric emptying and insulin accumulation dynamic were manually modelled with the result shown by the dashed line in Fig. 3. The day two simulations also include the sensor error shown in Fig. 3. Local hospital protocol generally sets the maximum insulin infusion rate at 6 U/h, however, due to the high glucose levels and large derivative, $\dot{G}$ following the OGTT dose, the control algorithm commanded up to 37 U/h for a given 15 min period. A constant infusion rate of approximately 6 U/h was required to maintain the final steady state blood glucose level, and along with the relatively low $S_I$ in Table 1, indicates this patient’s high insulin resistance. The result is an insulin profile that looks very similar to an insulin injection combined with a steady background infusion, matching current treatment protocols (Lam et al., 2002; Pickup and Keen, 2002).

Patient 3 was a 75 year old male with a head injury. Uncontrolled data from day one, in Fig. 4 shows the patient behaves essentially as a Type 1 diabetic, although not previously diagnosed. Insulin level tests confirmed this assumption with a very low insulin level of 3 pmol/L. The controlled glucose response simulation does not capture the unmodelled dip in the glucose profile at 180 min, or the initial stronger glucose rise, further illustrating how the simple insulin utilisation dynamics in Eq. (1) are not necessarily fully adequate. These results indicate that some insulin appears to accumulate, or take a slower path, in a remote compartment before utilisation, as shown by the dashed
line in Fig. 4 generated using an approximation of this dynamic in the model. This slower acting insulin accumulation has been recently proposed by other researchers (Hovorka, Chassin, Luzio, Playle, & Owens, 1998; Cobelli, Bettini, Caumo, & Quon, 1998).

Patient 4 was a 59 year old female with sepsis and infection. Day one of the trial gave an almost flat glucose response curve, implying the patient was both hyperglycaemic and (potentially) hyper-insulinaemic. However, the insulin level test was potentially infected as shown by the high insulin laboratory test measurement in Table 1. With the lack of a significant increase in glucose levels from basal and resulting low derivative values, the insulin infusion was effectively constant on day two. The sub-basal target glucose level ($G_t = 5.4$ mmol/L) was chosen $1$ mmol/L below the patient’s day two basal level of $G_B = 6.4$ mmol/L and the control algorithm proved efficient at obtaining this slightly reduced level. Fig. 5 also shows an initial dip in the measured data and simulation output on both controlled and uncontrolled data that may be attributed to an unmodelled delay in glucose uptake.

A comparison between the predicted and actual insulin dose for all four patients is shown in Table 2. The total insulin infused over four hours differed from the predicted insulin infusion total by no more than $10.4\%$ with an average error of approximately $3\%$ over the four trials. This strong correlation helps validate the fundamental models and methods employed, despite potential missing dynamics that must be added. Where the model tends to under predict insulin consumption, it can be attributed to one of at least three factors. First, the discrete $0.2$ U/mL insulin infusion levels are not the analogue values available in the model. Second is that for large doses, such as with patient 2, some insulin may be “lost” along the length of the infuser tubing or in physiological saturation dynamics that are not modelled. Third, the patient specific parameters, $p_C$ and $S_I$, may change over the trial period due to drug interactions or natural fluctuations.

To determine control effectiveness, blood glucose excursion is quantified as the sum of the area under the measured blood glucose curve above the basal glucose level, as illustrated in Fig. 6, where $A_1$ and $A_2$ denote the blood glucose excursion on day one and two, respectively. The ratio between the controlled, $A_2$, and uncontrolled areas, $A_1$, quantifies the effectiveness of the controller. The reduction in basal glucose level from the beginning, $G_B$, to the end of day two, $G_B(\text{final})$, measures the improvement obtained as the controller aims for the lower target basal glucose level. Fig. 6 illustrates both performance metrics. For the first four patients the excursion from basal blood glucose level is reduced $79–89\%$, and the basal glucose level is reduced $12–41\%$ with specific values given in Table 3.

The unmodelled accumulator dynamic noted in most of the clinical results has four potential causes. The first possible cause is the physiological battle between the body’s desire to return to the (elevated) basal level and the controller’s attempts to hold it down, as best seen in

---

**Table 2**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Model predicted total insulin (U)</th>
<th>Day 2 clinical trial total insulin (U)</th>
<th>Percentage difference between predicted and infused (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4.50</td>
<td>4.43</td>
<td>-1.6</td>
</tr>
<tr>
<td>2</td>
<td>38.24</td>
<td>42.65</td>
<td>10.4</td>
</tr>
<tr>
<td>3</td>
<td>4.90</td>
<td>4.50</td>
<td>-8.9</td>
</tr>
<tr>
<td>4</td>
<td>8.90</td>
<td>8.07</td>
<td>-10.0</td>
</tr>
</tbody>
</table>

---

Fig. 4. Patient 3 model vs. measured glucose—controlled and uncontrolled 75g OGTT.

Fig. 5. Patient 4 model vs. measured glucose—controlled and uncontrolled 75g OGTT.
Fig. 2. The second possibility is that the demand for insulin in the blood is secondary to those of the brain and liver, such that meeting these demands first causes a reduction in useful insulin in the blood and a later over reaction. Third, saturation in transport or utilisation could also lead to a delayed response as seen in these trials. Lastly, it is believed that insulo-penic, or very low insulin level, patients can develop lipo-toxicity, suppressing insulin release from any active beta cells. Therefore, when exogenous insulin is infused these beta cells are free to release endogenous insulin not initially accounted for (Del Prato et al., 2002). Further tests will help clarify the specific causes of this dynamic, and improve the models and clinical trial methods employed.

A second limitation of the proof of concept trials performed that should be noted is the lack of intermittent plasma insulin samples. This data would have aided any model verification, despite using a well-established model. It should be noted that the primary goal was to test the control algorithm, which used only glucose measurements as inputs to the controller, and that plasma insulin levels are not typically able to be determined as rapidly as glucose samples in a clinical environment. The latter aspect points to the potential for estimation of plasma insulin levels as a possible avenue to achieve better control.

Finally, the use of an OGTT to obtain patient specific parameters adds significant time and complexity, especially for a practical implementation. While the OGTT does provide a useful set of data on the patient specific glucose–insulin response a similar result can be seen with an insulin challenge using a fixed insulin bolus in the range of 1.5–2U. The OGTT and the insulin challenge provide similar data about the hyperglycaemic patient specific metabolic system response that can be used to fit the endogenous glucose removal and insulin sensitivity parameters \( p_G \) and \( S_I \). Another approach would be to use a default set of parameters based on data from the literature and then adapt these values as the trial progressed to obtain better accuracy between predicted and actual results from insulin and/or glucose inputs.

5. Conclusions

The research has succeeded in demonstrating tight feedback controlled blood glucose level regulation in response to a glucose input in critically ill-patients using a heavy-derivative controller. The first four trials show a good level of correlation between the simple model and patient data, verifying the basic models and methods employed. In particular, the model’s ability to capture the insulin dose to within 10% of actual values validates the fundamental assumptions made. More specifically, heavy derivative control has been demonstrated to be effective in practice and to match the essential dynamics encountered reasonably well, resulting in reductions in glucose excursion of up to 89% and basal glucose reductions of up to 41%. However, the results have also clearly demonstrated the need for additional dynamics in the system model. Hence, the simple glucose–insulin system model employed captures the fundamental dynamics well for these relatively short tests, but is likely too simple for long-term effectiveness over several hours or days. Finally, it has been shown that glucose challenges can be managed effectively and basal values reduced for the difficult hyperglycaemic critical care patient using this very simple feedback control method.

Additionally, two simple measures for capturing the effectiveness of automated glucose regulation are introduced. The comparison of blood glucose excursion area, for a given input, is seen to capture the essential details of the magnitude and duration of the blood glucose excursion from the patient’s basal level. Secondly, many ICU patients have elevated basal blood glucose levels so that comparing the final basal value that the controller achieves is a simple measure of the controller’s ability. Future developments include model development, parameter estimate improvements.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Day 1–OGTT</th>
<th>Day 2–clinical trial</th>
<th>( A_1 )</th>
<th>( A_2 )</th>
<th>( G_{Bf(final)} )</th>
<th>( G_{Bf(final)}/G_{B} )</th>
<th>( A_2/A_1 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9.6</td>
<td>292</td>
<td>7.2</td>
<td>60</td>
<td>6.1</td>
<td>0.85</td>
<td>0.21</td>
</tr>
<tr>
<td>2</td>
<td>12.5</td>
<td>1524</td>
<td>11.6</td>
<td>172</td>
<td>6.9</td>
<td>0.59</td>
<td>0.11</td>
</tr>
<tr>
<td>3</td>
<td>13.1</td>
<td>1082</td>
<td>11.1</td>
<td>196</td>
<td>7.9</td>
<td>0.71</td>
<td>0.18</td>
</tr>
<tr>
<td>4</td>
<td>10.8</td>
<td>170</td>
<td>6.4</td>
<td>23</td>
<td>5.6</td>
<td>0.88</td>
<td>0.14</td>
</tr>
</tbody>
</table>
including the use of insulin challenges instead of the OGTT, and enhancement of the control systems employed with an emphasis on adaptive control methods.

Acknowledgements

The authors wish to acknowledge Prof. Don Beaven, Dr. Helen Lunt, Professor Russell Scott and Jinny Willis Ph.D. of the Canterbury District Health Board and Otago School of Medicine for their support and input to this work. Additional thanks are due Dr. Anne Peters, Dr. Mayer Davidson, Dr. David Schriger and Dr. Vic Hasselblad for gladly sharing their data (Peters et al., 1996).

Funding for this research has been provided by the Intensive Care Medicine Trust at Christchurch Hospital and Diabetes New Zealand.

References


Hasselblad for gladly sharing their data (Peters et al., 1996). Additional thanks are due Dr. Anne Peters, Ph.D. of the Canterbury District Health Board and Diabetes New Zealand.


